Gold Star Distribution recalled PEPCID COMPLETE - 25CT on December 26, 2025 due to insanitary conditions, including rodent exposure. The recall affects all lots distributed by Gold Star and poses a high health risk. Consumers should stop using this product immediately and seek guidance from healthcare providers.
CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
Consumers and healthcare providers should stop using this product immediately. Contact GOLD STAR DISTRIBUTION INC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves all lots of PEPCID COMPLETE - 25CT distributed by Gold Star Distribution. The product was distributed nationwide in the U.S. Specific pricing information is not available.
The recall is due to CGMP deviations, specifically insanitary conditions in the distribution center, including rodent exposure and activity. This poses a risk of contamination and potential health hazards.
There are no specific reported incidents of injuries or illnesses associated with this recall. However, the high hazard level indicates a significant risk of health complications if consumed.
Consumers should immediately stop using PEPCID COMPLETE - 25CT. Contact Gold Star Distribution or a healthcare provider for further guidance. Notifications will be communicated via email, fax, letter, press release, and telephone.
For more information, call Gold Star Distribution at 1-800-XXX-XXXX or visit the FDA's enforcement report page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0276-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.